Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Status:
Recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).

Phase 2

Alexion Pharmaceuticals